Overview
We are developing and commercializing novel, proprietary products and technologies that are intended to make the blood supply safer. We are commercializing the INTERCEPT Blood System for platelets and plasma in Europe and in 2006, we initiated a Phase I clinical trial for our INTERCEPT Blood System for red blood cells in the United States. The INTERCEPT Blood System, which is based on our proprietary Helinx technology for controlling biological replication, is designed to enhance the safety of donated blood components by inactivating viruses, bacteria, parasites and other pathogens, as well as potentially harmful white blood cells.
|
